News | November 13, 2014

SPECT-Guided Treatment Improves Outcomes in Psychiatric Patients

SPECT imaging, Vancouver, psychiatry, mental health

Nov. 13, 2014 — A new study by clinicians and researchers from Toronto and Vancouver, Canada, found that psychiatric patients who underwent SPECT-influenced treatments improved significantly more than patients who did not.

Published in the Journal of Neuropsychiatry, the study used SPECT imaging – Single Photon Emission Computed Tomography that measures blood flow and shows over-activity, under-activity or non-activity in the brain. The research shows that SPECT imaging is a potentially helpful tool to gain more information on patients who struggle with mental health issues and thus better target their treatment.

Daniel Amen, M.D., Founder of Amen Clinics who is not related to the research says, "This study points to a significant advancement in the care of people who suffer with mental health issues. Until now, standard diagnoses in psychiatry are made primarily through talking to patients and looking at symptom clusters without any biological information. Psychiatry is the only medical specialty that virtually never looks at the organ it treats. It is a major step forward."

Researchers and clinicians have debated the clinical benefits of SPECT for decades, but ongoing new research consistently is showing its value in clinical practice.

The clinicians involved in the study have been using SPECT in clinical practice for nearly a decade and have recruited other physicians in Canada to do the same. There are a number of clinics in the United States, Japan and Chili who use SPECT on a regular basis.

Results from Toronto and Vancouver, Canada study not only support SPECT imaging science in treating patients for improved outcomes, but also aids the debate – supporting that SPECT is a groundbreaking tool that should be used in treatment of mental healthf.

For more information: hneuro.psychiatryonline.org

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...